Centyrin ligands for extrahepatic delivery of siRNA

RNA interference (RNAi) offers the potential to treat disease at the earliest onset by selectively turning off the expression of target genes, such as intracellular oncogenes that drive cancer growth. However, the development of RNAi therapeutics as anti-cancer drugs has been limited by both a lack...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Donna, Goldberg, Shalom, Theile, Christopher S., Dambra, Richard, Haskell, Kathleen, Kuhar, Elise, Lin, Tricia, Parmar, Rubina, Manoharan, Muthiah, Richter, Mark, Wu, Meizhen, Mendrola Zarazowski, Jeannine, Jadhav, Vasant, Maier, Martin A., Sepp-Lorenzino, Laura, O’Neil, Karyn, Dudkin, Vadim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178446/
https://www.ncbi.nlm.nih.gov/pubmed/33601052
http://dx.doi.org/10.1016/j.ymthe.2021.02.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178446/
https://www.ncbi.nlm.nih.gov/pubmed/33601052
http://dx.doi.org/10.1016/j.ymthe.2021.02.015

Ejemplares similares